Document is current
Any future updates will be listed below
-
Authors
Ibrahim, Khalid A. https://orcid.org/0000-0003-1819-1952
Cathala, Camille https://orcid.org/0009-0000-5755-9209
Bevilacqua, Carlo https://orcid.org/0000-0001-9084-0641
Feletti, Lely https://orcid.org/0009-0001-4413-3396
Prevedel, Robert https://orcid.org/0000-0003-3366-4703
Lashuel, Hilal A.
Radenovic, Aleksandra https://orcid.org/0000-0001-8194-2785
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CRSII5_193740)
- License Information
-
More Information
Article History
Received: 8 January 2025
Accepted: 9 June 2025
First Online: 24 July 2025
Competing interests
: H.A.L. has received funding from the industry to support research on neurodegenerative diseases, including from Merck Serono, UCB and AbbVie. These companies had no specific role in the conceptualization, preparation, or decision to publish this work. H.A.L. is also the co-founder and Chief Scientific Officer of ND BioSciences SA, a company that develops diagnostics and treatments for neurodegenerative diseases based on platforms that reproduce the complexity and diversity of proteins implicated in neurodegenerative diseases and their pathologies. All remaining authors declare no competing interests.
